COMP <GO>
CRL vs ABBV // EV/EBITDA & P/E VALUATION
Charles River Laboratories International Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CRL 1
— ABBV 12
▲ EV/EBITDA & P/E VALUATION LEADER: ABBV
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
valuation
95.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 29.00% | -28.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 3.47% | -0.37 | ABBV | /fcf-yield <GO> |
| Operating Margin | 0.60% | 24.60% | -24.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 6.90% | -10.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 8.60% | -9.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 5.33 | -1.68 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 72.8 | -4.73 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 113.1x | -90.10 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $513.86B | -$495.91B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | ABBV REV | CRL GROSS % | ABBV GROSS % | CRL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $61.16B | 44.0% | 70.2% | $557.0M | $17.82B |
| FY 2024 | $4.05B | $56.33B | 44.0% | 70.0% | $552.3M | $17.83B |
| FY 2023 | $4.13B | $54.32B | 44.0% | 44.0% | $498.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
ABBV // BETA 1.15